

ZytoLight® Glioma 1p/19q Probe Set



Background

Deletions affecting the short arm of chromosome 1 (1p36) and the long arm of chromosome 19 (19q13) are frequently found in human gliomas. According to the 2016 WHO criteria for classification of tumors of the central nervous system, the detection of 1p/19q loss is required for the diagnosis of WHO grade II or III "oligodendroglioma, IDH-mutant and 1p/19q codeleted". Since both, astrocytomas and oligodendrogliomas, can exhibit IDH mutations, evaluation of 1p/19q status plays a critical role in differentiating astrocytoma from oligodendroglioma. Oligodendroglioma morphology, IDH-mutant genotype, and 1p/19q codeletion are associated with better response to chemotherapy and improved survival. Hence, determination of 1p and 19q status may aid in therapeutic decisions and predict outcome in patients with diffuse gliomas.

Several types of tissue tend to emit intense autofluorescence including brain, liver, kidney and myocardium, making it difficult to evaluate FISH results. The ZyBlack™ Quenching Solution reduces autofluorescence without adversely affecting tissue integrity or specific fluorescence signals.



References

- Barbashina V, et al. (2005) Clin Cancer Res 11: 1119-28.
- Cairncross JG, et al. (1998) J Natl Cancer Inst 90: 1473-9.
- Cairncross G, et al. (2013) J Clin Oncol 31: 337-43.
- Griffin CA, et al. (2006) J Neuropathol Exp Neurol 65: 988-94.
- Louis DN, et al. (ed.) (2016) WHO Classification of Tumours of the Central Nervous System (Revised 4th Edition).
- Reifenberger G, et al. (2017) Nat Rev Clin Oncol 14: 434-52.
- Rosenberg JE, et al. (1996) Oncogene 13: 2483-5.
- Smith JS, et al. (1999) Oncogene 18: 4144-52.
- Smith JS, et al. (2000) Genes Chromosomes Cancer 29: 16-25.



Probe Description

The ZytoLight® Glioma 1p/19q Probe Set includes the ZytoLight® SPEC 1p36/1q25 Dual Color Probe and the ZytoLight® SPEC 19q13/19p13 Dual Color Probe for the detection of both 1p36 and 19q13 loci, and the innovative ZyBlack™ Quenching Solution to reduce autofluorescence on both formalin-fixed paraffin-embedded and frozen sections.

ZytoLight® SPEC 1p36/1q25 Dual Color Probe




ZytoLight® SPEC 19q13/19p13 Dual Color Probe




Results

Using the SPEC 1p36/1q25 Dual Color Probe or the SPEC 19q13/19p13 Dual Color Probe in a normal interphase nucleus, two orange and two green signals are expected. In a cell with deletions affecting the 1p36 or 19q13 locus, one or no copy of the orange signal will be observed.



Brain tissue section hybridized with the ZytoLight® SPEC 1p36/1q25 Dual Color Probe without ZyBlack™ Quenching Solution.



Brain tissue section hybridized with the ZytoLight® SPEC 1p36/1q25 Dual Color Probe with ZyBlack™ Quenching Solution.

Prod. No.	Product	Label	Tests* (Volume)
Z-2272-20	ZytoLight Glioma 1p/19q Probe Set CE IVD Incl. ZytoLight SPEC 1p36/1q25 Dual Color Probe, 0.2 ml; ZytoLight SPEC 19q13/19p13 Dual Color Probe, 0.2 ml; ZyBlack Quenching Solution, 8 ml		20
Related Products			
Z-2075-200	ZytoLight SPEC 1p36/1q25 Dual Color Probe CE IVD	●/●	20 (200 µl)
Z-2076-200	ZytoLight SPEC 19q13/19p13 Dual Color Probe CE IVD	●/●	20 (200 µl)
Z-2028-20	ZytoLight FISH-Tissue Implementation Kit CE IVD Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 560 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraText-Solution, 0.8 ml		20

* Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.